

The role of laparoscopic gastric bypass in the prevention and management of type 2 diabetes.

Xiaojun Zhang*

Department of General Surgery, Chinese Academy of Sciences, Zhejiang, China

Introduction

Type 2 diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels. It is a significant global health concern due to its increasing prevalence and association with various complications. Laparoscopic gastric bypass (LGB) has emerged as an effective surgical intervention for weight loss and has shown promising outcomes in the prevention and management of type 2 diabetes. This article aims to explore the role of LGB in preventing and managing type 2 diabetes and its underlying mechanisms [1,2].

Numerous studies have demonstrated the preventive effects of LGB on type 2 diabetes development in individuals at high risk. In these individuals, LGB has shown to induce substantial and sustained weight loss, leading to a reduction in insulin resistance and improved glycemic control. Long-term follow-up studies have reported a significant reduction in the incidence of type 2 diabetes among patients who underwent LGB compared to non-surgical interventions or conventional medical treatment [3].

Management of type 2 diabetes

LGB has also shown remarkable efficacy in the management of existing type 2 diabetes. Studies have reported substantial improvement or remission of diabetes following LGB, with many patients experiencing reduced medication dependence or even complete discontinuation of antidiabetic medications. The rapid and significant weight loss achieved through LGB positively affects insulin sensitivity and beta-cell function, resulting in improved glycemic control and reduced long-term complications associated with diabetes.

In addition to its glycemic benefits, LGB has been shown to improve several metabolic parameters associated with type 2 diabetes. These include reductions in blood pressure, low-density lipoprotein cholesterol, triglycerides, and markers of inflammation. Furthermore, LGB has demonstrated positive effects on cardiovascular risk factors, such as increased high-density lipoprotein cholesterol and improved endothelial function, leading to a decreased risk of cardiovascular disease in patients with type 2 diabetes [4].

Patient selection is crucial for optimizing outcomes after LGB. Candidates should be carefully evaluated based on their comorbidities, body mass index, and diabetes duration. Long-term follow-up studies have shown sustained improvements in glycemic control and diabetes-related comorbidities following LGB. However, regular monitoring and multidisciplinary care are essential to address potential nutritional deficiencies and ensure optimal outcomes.

Laparoscopic gastric bypass has demonstrated a significant role in both the prevention and management of type 2 diabetes. Through various mechanisms, including weight loss, hormonal changes, and alterations in gut microbiota, LGB offers substantial improvements in glycemic control, insulin sensitivity, and metabolic parameters. However, careful patient selection and long-term follow-up are necessary to maximize the benefits and minimize potential risks associated with this surgical intervention. Further research is warranted to explore the long-term effects and determine the optimal protocols for LGB in the prevention and management of type 2 diabetes [5].

References

1. Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes-A systematic review. *Diabetes/Metab Res Rev.* 2004;20(6):438-45.
2. Meneghini LF. Impact of bariatric surgery on type 2 diabetes. *Cell Biochem Biophys.* 2007;48:97-102.
3. Alqunai MS, Alrashid FF. Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: A review article. *Am J Transl Res.* 2022;14(2):1160.
4. Guraya SY, Strate T. Surgical outcome of laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass for resolution of type 2 diabetes mellitus: A systematic review and meta-analysis. *World J Gastroenterol.* 2020;26(8):865.
5. Panosian J, Ding SA, Simonson DC, et al. Physical activity in obese type 2 diabetes after gastric bypass or medical management. *Am J Med.* 2017;130(1):83-92.

*Correspondence to: Xiaojun Zhang, Department of General Surgery, Chinese Academy of Sciences, Zhejiang, China, E mail: xiaojun22@zhang.cn

Received: 01-Jul-2023, Manuscript No. AACRSIP-23-104896; Editor assigned: 04-Jul-2023, PreQC No. AACRSIP-23-104896(PQ); Reviewed: 18-Jul-2023, QC No. AACRSIP-23-104896; Revised: 21-Jul-2023, Manuscript No. AACRSIP-23-104896(R); Published: 28-Jul-2023, DOI:10.35841/aacrsip-7.4.159